Teva Pharmaceutical Industries Limited (TEVJF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Teva Pharmaceutical Industries Limited (TEVJF) trades at $30.34 with AI Score 54/100 (Grade B). Teva Pharmaceutical Industries Limited develops, manufactures, and markets generic and specialty medicines globally. Market cap: $35.33B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for TEVJF: TEVJF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TEVJF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TEVJF: 3/4 perspectives are bullish. Dominant signal: Moon AI bullish.
Teva Pharmaceutical Industries Limited (TEVJF) Healthcare & Pipeline Overview
Teva Pharmaceutical Industries Limited is a global pharmaceutical company specializing in generic and specialty medicines, with a focus on central nervous system, respiratory, and oncology products. The company operates in North America, Europe, and internationally, offering a wide range of dosage forms and active pharmaceutical ingredients, demonstrating a diversified approach within the healthcare sector.
What Is the Investment Thesis for TEVJF?
Teva Pharmaceutical Industries Limited presents a complex investment case. With a market capitalization of $32.47 billion and a P/E ratio of 23.90, the company's valuation reflects both its established market presence and the challenges it faces. A key value driver is its diverse portfolio of generic and specialty medicines, providing multiple revenue streams across different therapeutic areas. Growth catalysts include the continued expansion of its specialty drug portfolio, such as AJOVY and AUSTEDO, and strategic collaborations like the one with MedinCell. The company's gross margin of 51.8% indicates solid profitability. However, potential risks include competition from other generic manufacturers, patent expirations, and regulatory challenges. Monitoring the performance of key products and the success of its pipeline will be crucial in assessing Teva's long-term growth potential.
Based on FMP financials and quantitative analysis
TEVJF Key Highlights
- Market Cap of $32.47 billion reflects Teva's significant presence in the global pharmaceutical market.
- P/E ratio of 23.90 indicates the price investors are willing to pay for each dollar of Teva's earnings.
- Gross Margin of 51.8% demonstrates Teva's ability to efficiently produce and sell its products.
- Profit Margin of 8.2% shows the percentage of revenue that turns into profit after all expenses.
- Beta of 0.72 suggests that Teva's stock price is less volatile than the overall market.
Who Are TEVJF's Competitors?
TEVJF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALPMY Astellas Pharma Inc. | $13.42 | +1.21% | $24.04B | 55 |
| CLPBF Coloplast A/S | $57.56 | +0.00% | $11.94B | 47 |
| CLPBY Coloplast A/S | $6.00 | +1.52% | $13.52B | 48 |
| ORINY Orion Oyj | $37.99 | +0.00% | $21.38B | 64 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TEVJF's Key Strengths?
- Diverse portfolio of generic and specialty medicines.
- Global presence in North America, Europe, and other international markets.
- Established manufacturing and distribution infrastructure.
- Active pharmaceutical ingredients (API) business.
What Are TEVJF's Weaknesses?
- Exposure to generic competition and pricing pressures.
- Patent expirations on key products.
- Regulatory challenges and compliance risks.
- High debt levels.
What Could Drive TEVJF Stock Higher?
- Potential FDA approvals for new specialty drugs in Teva's pipeline.
- Continued expansion of Teva's biosimilar portfolio.
- Strategic partnerships and collaborations to develop innovative therapies.
- Cost-cutting initiatives to improve profitability and reduce debt.
- Growth in emerging markets driven by increasing healthcare spending.
What Are the Key Risks for TEVJF?
- Intense competition from other generic pharmaceutical companies.
- Patent expirations on key products leading to revenue decline.
- Regulatory challenges and compliance risks.
- Product liability claims and litigation.
- Economic downturns and currency fluctuations impacting global operations.
What Are the Growth Opportunities for TEVJF?
- Expansion of Specialty Drug Portfolio: Teva has the opportunity to grow its revenue through its specialty drug portfolio, particularly AJOVY for migraine prevention and AUSTEDO for tardive dyskinesia. The market for migraine treatments is expected to grow, driven by increasing awareness and diagnosis rates. AUSTEDO also addresses a significant unmet need in the treatment of tardive dyskinesia. Successful commercialization and expansion of these products can drive significant revenue growth for Teva over the next 3-5 years.
- Strategic Collaborations and Partnerships: Teva's collaboration with MedinCell to develop long-acting injectable products represents a significant growth opportunity. Long-acting injectables offer improved patient adherence and convenience, addressing a key challenge in chronic disease management. The risperidone suspension for schizophrenia treatment, developed in partnership with MedinCell, has the potential to capture a significant share of the schizophrenia treatment market. This partnership can drive innovation and expand Teva's product offerings in the CNS therapeutic area.
- Growth in Emerging Markets: Expanding its presence in emerging markets presents a substantial growth opportunity for Teva. These markets are characterized by increasing healthcare spending, growing populations, and rising demand for affordable medicines. By tailoring its product offerings to meet the specific needs of these markets, Teva can tap into new revenue streams and diversify its geographic footprint. Focus on key emerging markets in Asia, Latin America, and Eastern Europe can drive long-term growth.
- Biosimilar Development and Commercialization: Teva can capitalize on the growing biosimilars market by developing and commercializing biosimilar versions of branded biologic drugs. Biosimilars offer a more affordable alternative to expensive biologic therapies, addressing the increasing pressure to reduce healthcare costs. By investing in biosimilar development, Teva can capture a share of this rapidly growing market and expand its product portfolio. Focus on biosimilars for oncology and autoimmune diseases can drive significant revenue growth.
- Active Pharmaceutical Ingredients (API) Business: Teva's API business represents a stable and profitable revenue stream. The company can further grow this business by expanding its API portfolio and strengthening its relationships with pharmaceutical manufacturers. The demand for APIs is driven by the increasing production of generic drugs and the growing pharmaceutical industry. By focusing on high-quality APIs and reliable supply chains, Teva can maintain its competitive advantage and drive growth in its API business.
What Opportunities Does TEVJF Have?
- Expansion of specialty drug portfolio.
- Strategic collaborations and partnerships.
- Growth in emerging markets.
- Biosimilar development and commercialization.
What Threats Does TEVJF Face?
- Increased competition from other generic manufacturers.
- Changes in healthcare regulations and reimbursement policies.
- Product liability claims and litigation.
- Economic downturns and currency fluctuations.
What Are TEVJF's Competitive Advantages?
- Scale: Teva is one of the largest generic pharmaceutical companies in the world, allowing it to achieve economies of scale in manufacturing and distribution.
- Product Portfolio: Teva has a diverse portfolio of generic and specialty medicines, reducing its reliance on any single product.
- Global Presence: Teva operates in North America, Europe, and other international markets, providing geographic diversification.
- API Business: Teva's active pharmaceutical ingredients (API) business provides a stable and profitable revenue stream.
What Does TEVJF Do?
Founded in 1901 and headquartered in Tel Aviv-Yafo, Israel, Teva Pharmaceutical Industries Limited has evolved into a leading global pharmaceutical company. The company develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products across North America, Europe, and other international markets. Teva offers a broad portfolio of products, including sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. Teva's therapeutic focus spans several key areas, including the central nervous system (CNS), pain management, respiratory, and oncology. Key CNS products include Copaxone for relapsing forms of multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for tardive dyskinesia and chorea associated with Huntington disease. In the respiratory market, Teva offers ProAir, QVAR, and other inhalers for asthma and chronic obstructive pulmonary disease (COPD). Its oncology portfolio includes Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva also develops and sells active pharmaceutical ingredients (APIs) and has a collaboration with MedinCell for long-acting injectable products, including a risperidone suspension for schizophrenia treatment. Teva's global presence and diverse product offerings position it as a significant player in the pharmaceutical industry.
What Products and Services Does TEVJF Offer?
- Develops generic medicines.
- Manufactures generic medicines.
- Markets generic medicines.
- Distributes generic medicines.
- Develops specialty medicines.
- Manufactures specialty medicines.
- Markets specialty medicines.
- Distributes specialty medicines.
How Does TEVJF Make Money?
- Develops and manufactures a wide range of generic pharmaceutical products.
- Creates and markets specialty medicines focused on specific therapeutic areas.
- Sells active pharmaceutical ingredients (APIs) to other pharmaceutical companies.
What Industry Does TEVJF Operate In?
Teva Pharmaceutical Industries Limited operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The global market for generic drugs is driven by increasing healthcare costs and the expiration of patents on branded pharmaceuticals. Teva competes with other major generic manufacturers, as well as companies focused on innovative specialty drugs. The industry is also influenced by trends such as biosimilar development and the growing demand for affordable medicines. Teva's diversified portfolio and global presence position it to capitalize on these trends, but it must also navigate pricing pressures and regulatory changes.
Who Are TEVJF's Key Customers?
- Pharmacies and retail drug stores.
- Hospitals and healthcare providers.
- Governmental and private healthcare insurers.
- Other pharmaceutical companies (for APIs).
TEVJF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
TEVJF Latest News
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
-
New 52-Week Lows For Monday Morning
· Aug 5, 2019
TEVJF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TEVJF.
Price Targets
Wall Street price target analysis for TEVJF.
TEVJF MoonshotScore
What does this score mean?
The MoonshotScore rates TEVJF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard D. Francis
CEO
Richard D. Francis serves as the CEO of Teva Pharmaceutical Industries Limited. His career spans various leadership roles in the pharmaceutical industry. Before joining Teva, he held significant positions at Sandoz, the generics division of Novartis, where he was responsible for driving growth and innovation. His experience includes global commercial operations, strategic planning, and portfolio management. Francis brings a wealth of knowledge in both generic and specialty pharmaceuticals, positioning him to lead Teva through its current challenges and opportunities.
Track Record: Since assuming the role of CEO, Richard D. Francis has focused on streamlining Teva's operations, reducing debt, and driving growth in key therapeutic areas. He has overseen strategic initiatives to optimize the company's product portfolio and improve its financial performance. His leadership is aimed at positioning Teva for long-term success in the competitive pharmaceutical market.
TEVJF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) securities. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited reporting requirements and may not meet the minimum financial standards required for exchange listing. This tier includes companies with speculative ventures, distressed assets, or those that are unable or unwilling to provide audited financial statements. Investing in OTC Other securities carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Information: Lack of publicly available financial information increases investment risk.
- Low Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Price Volatility: OTC stocks are often subject to significant price swings.
- Regulatory Scrutiny: OTC companies may face increased regulatory scrutiny.
- Potential for Fraud: Higher risk of fraudulent activity compared to exchange-listed companies.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the company's capital structure and debt levels.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Established History: Teva has a long history as a pharmaceutical company, which can be a positive sign.
- Global Operations: Teva operates in multiple countries, suggesting a degree of legitimacy.
- Product Portfolio: Teva has a diverse portfolio of generic and specialty medicines.
- Employee Count: The company employs a significant number of people, indicating a substantial operation.
- Collaboration with MedinCell: Partnership with MedinCell suggests external validation.
What Investors Ask About Teva Pharmaceutical Industries Limited (TEVJF) — Healthcare
What does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic and specialty medicines. The company's product portfolio includes treatments for central nervous system disorders, pain, respiratory conditions, and cancer. Teva also develops and sells active pharmaceutical ingredients (APIs) to other pharmaceutical companies. Its business model focuses on providing affordable generic medicines and innovative specialty therapies to patients worldwide, while navigating a complex regulatory landscape and competitive market.
What do analysts say about TEVJF stock?
Analyst consensus on TEVJF stock is mixed, reflecting the company's complex financial situation and competitive environment. Key valuation metrics, such as the P/E ratio of 23.90, suggest that the stock is trading at a premium compared to some of its peers. Growth considerations include the potential for new product launches, strategic partnerships, and cost-cutting initiatives to drive future earnings. However, analysts also note the risks associated with generic competition, patent expirations, and regulatory challenges. The overall sentiment is cautiously optimistic, with a focus on monitoring the company's progress in executing its strategic plan.
What are the main risks for TEVJF?
Teva Pharmaceutical Industries Limited faces several key risks, including intense competition from other generic drug manufacturers, which can lead to pricing pressures and reduced market share. Patent expirations on key products pose a significant threat to revenue streams, as generic versions enter the market. Regulatory challenges and compliance risks, such as those related to product safety and manufacturing standards, can also impact the company's operations and financial performance. Additionally, product liability claims and litigation represent an ongoing risk, particularly in the pharmaceutical industry. Economic downturns and currency fluctuations can affect Teva's global operations and profitability.
What are the key factors to evaluate for TEVJF?
Teva Pharmaceutical Industries Limited (TEVJF) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does TEVJF data refresh on this page?
TEVJF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TEVJF's recent stock price performance?
Teva Pharmaceutical Industries Limited (TEVJF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse portfolio of generic and specialty medicines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TEVJF overvalued or undervalued right now?
Valuing Teva Pharmaceutical Industries Limited (TEVJF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TEVJF?
Before investing in Teva Pharmaceutical Industries Limited (TEVJF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may have limited availability and reliability.
- AI analysis pending for TEVJF may provide further insights in the future.